Anika Therapeutics, Inc. (ANIK) Tops Q1 Revenue Tops Views
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.50 --0%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
GNLN, AFIB, USDP, More
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
GNLN, AFIB, USDP, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q1 EPS of $0.97, $0.72 better than the analyst estimate of $0.25. Revenue for the quarter came in at $34 million versus the consensus estimate of $16.03 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- Empire Petroleum posts $11.1M revenue in Q2 2026, narrows net loss
- S&P 500 eyes record as retail slump, Iran risk set up pivotal week
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
